SCHÖNEFELD/BERLIN, Germany – November 17, 2025 – Captain T Cell, a biotechnology company developing next-generation TCR-T cell therapies for solid tumors, today announced the successful closing of an equity financing round with both new and existing investors. The latest equity funding, along with already secured grants, provides Captain T Cell with a total budget of EUR 20 million to advance...

SCHÖNEFELD, Germany – June 30, 2025 – Captain T Cell, a biotech company developing next-generation TCR-T cell therapies for solid tumors, today announced that the National Center for Tumor Diseases (NCT) has awarded funding to Charité – Universitätsmedizin Berlin for an ...

BERLIN, Germany – June 17, 2025 – Captain T Cell GmbH, a biotech company developing next-generation TCR-based cell therapies for patients with solid tumors, today announced that it has been selected for residency in the Bayer Co.Lab incubator in Berlin. The Bayer Co.Lab program supports cutting-edge ...

WILMINGTON, Mass. – June 17, 2024 – Charles River Laboratories International, Inc. (NYSE: CRL) and Captain T Cell, a spinoff from the renowned Max Delbrück Center Berlin, Germany, today announced a plasmid DNA and retrovirus vector production program agreement. As part of Charles River’s Cell and Gene Therapy (CGT) Accelerator Program (CAP), ....

Schoenefeld/Berlin, Germany, May 22, 2024 — Captain T Cell GmbH, a biotechnology company developing next-generation T cells against solid tumors, today announced the successful closing of a seed financing round totaling € 8.5 million. A syndicate of experienced life science investors including i&i Biotech Fund I SCSp, Brandenburg Kapital GmbH, and HIL-INVENT Ges.m.b.H participated in the round. In addition, ….